trial suspension.

Key Considerations:

• Expiry date is based on completed stability studies
• Retest date applies when requalification is permitted
• Storage and transport conditions directly impact expiry validity

Labeling Requirements for Stability and Expiry:

Labels on IPs must clearly display expiration or retest dates. For blinded trials, codes must not reveal expiry information that can unblind the treatment arm.

Compliant labeling practices are outlined in GMP documentation.

Labeling Best Practices:

• Use clear “EXP” or “RTD” terminology
• Include storage conditions and protection requirements
• Apply expiration date to all packaging levels
• Ensure re-labeled products reflect accurate new expiry (if extended)

Storage and Environmental Monitoring:

Stability depends on maintaining storage conditions within the specified range. All storage equipment must be validated and monitored continuously.

Storage Compliance Checklist:

1. Calibrated refrigerators/freezers with data loggers
2. 24/7 environmental monitoring systems
3. Defined alert and alarm response protocols
4. Back-up power sources and excursion tracking

Tracking IP Expiry at Clinical Sites:

Sites are responsible for logging expiry dates and confirming that no expired IP is dispensed. Expiry status should be reviewed regularly and during each subject visit.

Tracking Tools:

• IP Inventory Log with batch-wise expiry tracking
• Expiry Alert Calendars or IWRS notifications
• Regular inventory audits by clinical research associates (CRAs)
• Automated expiry tracking systems, if integrated

For structured templates and tracking formats, refer to Pharma SOP templates.

Managing Expiry Date Extensions:

Sometimes, based on ongoing stability data, sponsors may extend expiry or retest dates. This must be communicated formally, with appropriate documentation and relabeling activities.

Steps for Expiry Extension Implementation:

1. Receive formal sponsor notification with revised expiry data
2. Verify data with Qualified Person (QP) or regulatory authority, if needed
3. Re-label IPs under controlled, documented procedures
4. Update site inventory logs and train staff

Deviation Handling and Excursion Documentation:

Using expired IP or encountering a temperature excursion can lead to non-compliance. Sponsors and sites must have predefined procedures to investigate and respond to such events.

Deviation Response Plan:

• Immediately quarantine impacted IPs
• Initiate deviation report with full root cause analysis
• Evaluate product usability based on stability data
• Document CAPA and notify regulatory authorities if required

Audit-Ready Documentation and Regulatory Compliance:

Agencies such as EMA and TGA expect documented evidence of expiry monitoring during inspections. All decisions related to stability, retesting, and expiry must be traceable and justified.

Documentation Must Include:

• Stability study reports and protocol references
• Shipping and storage temperature records
• Expiry update communications
• Deviation logs and corrective action records

Training and Oversight:

All personnel handling IPs must be trained in expiry monitoring protocols and aware of the implications of dispensing expired drugs. Sponsors should incorporate these checks into routine monitoring visits.

Training Focus Areas:

• Understanding expiry vs. retest dates
• Storage compliance and alert handling
• Label verification before dispensation
• Documentation and audit readiness

Additionally, real-time training feedback loops should be included in site visit reports to evaluate risk proactively.

Conclusion:

Investigational product stability and expiry date monitoring are essential safeguards in clinical trials. By rigorously following best practices for labeling, storage, documentation, and staff training, stakeholders can protect trial integrity and participant safety. An efficient, audit-ready system for stability and expiry ensures both regulatory success and scientific credibility across clinical studies.